Professor Sanjoy Paul is an internationally recognised clinical trialist, biostatistician and a real-world electronic medical record (EMR) data scientist with long-standing experience in design and conduct of clinical trials and pharmaco-epidemiological studies in the fields of metabolic diseases. Prof Paul’s current role is Chair Professor of Clinical Biostatistics, Epidemiology & Health Services Research, University of Melbourne, and Director of the Melbourne EpiCentre, a collaborative centre of research excellence. Prior to moving to Australia, Prof.Paul created the Statistics & Modelling Group of the University of Oxford Centre for Diabetes, Endocrinology and Metabolism in the UK.
Prof Paul is recognized for his leading role in the strategic development of industry-academia collaborations to identify new scopes with the real-world electronic medical records (EMRs) – addressing the logistic and methodological challenges in the conduct of comparative effectives and safety studies – with special emphasis on establishing the acceptability of the EMR based studies for regulatory considerations. His strategic achievements include playing pivotal roles in developing strategies to conduct clinical and pharmaco-epidemiological studies of high public health importance combining clinical trials and large real world data. He is actively involved in the strategic aspects of Australian federal government and Victorian state government’s initiatives to develop EMRs in Australia.
Prof Paul continues to play a pivotal role in the development of Australia’s translational research capabilities as one of the principal research leaders receiving National Collaborative Research Infrastructure Strategy (NCRIS) funding through Therapeutic Innovation Australia. He also acts as an expert advisor to Therapeutic Goods Administration of Australia (TGA) and programmes led by his international academic and industry collaborators.
In addition to attracting significant competitive research grants (~$19 million since 2010) from NHMRC, the Commonwealth government, and pharmaceutical companies, he has successfully built highly productive collaborations with international institutes and multinational pharmaceutical companies, including Imperial College London, University of Oxford, Peking University, Roche, AstraZeneca and Novo Nordisk. Prof Paul played an instrumental role in designing large multi- national outcome trials to conduct cardiovascular safety studies with anti-diabetes drugs (TECOS and ACE trials). He played a leading role in landmark studies in diabetes and cardiovascular diseases that have received widespread international acclaim, including the “UKPDS Post-trial Monitoring Study”, and the “Treating To Target In Type 2 Diabetes” trial. Currently Prof Paul is running 8 early and late phase multicenter/multinational clinical trials, and leading pharmaco-epidemiological studies in the fields of auto-immune and metabolic diseases combining clinical trial and large EMRs. He has designed, written study protocols and statistical analysis plans for over 100 funded clinical studies.
Prof Paul has published in highly acclaimed research journals that include the New England Journal of Medicine (NEJM), Diabetes, Diabetes Care, Diabetologia, Science Translational Medicine, Clinical Infectious Diseases and Diabetes Obesity & Metabolism, with more than 7000 citations over last 5 years and M-Index of 1.9, having commenced his research career in 2004. Three of his publications are recommended in the prestigious Faculty of 1000, and have attracted editorials in NEJM.